Navigation Links
Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, Suggest High and Durable Responses in Relapsed/Refractory Mantle Cell Lymphoma
Date:12/11/2012

redict", "intend" and similar expressions are intended to identify such forward-looking statements. These forward-looking statements are based on information currently available to us and are subject to a number of risks, uncertainties and other factors that could cause our actual results, performance or achievements to differ materially from those projected in, or implied by, these forward-looking statements. Factors that may cause such a difference include, without limitation, our need for substantial additional financing and the availability and terms of any such financing, the safety and/or efficacy results of clinical trials of our product candidates, our failure to obtain regulatory approvals or comply with ongoing governmental regulation, our ability to commercialize, manufacture and achieve market acceptance of any of our product candidates, for which we rely heavily on collaboration with third parties, and our ability to protect and enforce our intellectual property rights and to operate without infringing upon the proprietary rights of third parties. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, performance or achievements and no assurance can be given that the actual results will be consistent with these forward-looking statements. For more information about the risks and uncertainties that may affect our results, please see the Risk Factors section of our filings with the Securities and Exchange Commission, including our annual report on Form 10-K and quarterly reports on Form 10-Q. We do not intend to update any of the forward-looking statements after the date of this announcement to conform these statements to actual results, to changes in management's expectations or otherwise, except as may be required by law.

Note: Data in this release correspond to ASH Abstract 904.


'/>"/>
SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Six-Year Follow-Up Data for SPRYCEL®? (dasatinib) 100 mg Once Daily Demonstrates 71 Percent Overall Survival in Patients with Chronic-Phase Chronic Myeloid Leukaemia Resistant or Intolerant to Imatinib
2. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
3. VeriStrat® Test Results Correlate with Survival Outcomes in Advanced Lung Cancer
4. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
5. Alexza to Announce 2012 First Quarter Financial Results on Thursday, May 10, 2012
6. 3SBio Inc. Schedules Unaudited First Quarter 2012 Results
7. Simcere Pharmaceutical Group to Announce First Quarter 2012 Financial Results on Wednesday, May 9, 2012
8. Perrigo Company Will Release Third Quarter Fiscal 2012 Results On May 8, 2012
9. Genomic Health to Announce First Quarter 2012 Financial Results and Host Conference Call on Wednesday, May 2, 2012
10. Nektar to Announce Financial Results for the First Quarter of 2012 on Wednesday, May 2, 2012, After Close of U.S.-Based Financial Markets
11. STAAR Surgical Announces First Quarter 2012 Results Release Date and Conference Call and Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... MELBOURNE, Australia , Sept. 18, 2014 ... appointments of Dr. Ashraf Hanna , M.D., Ph.D., ... its Board of Directors. Dr. Hanna is the Vice ... and Chief Financial Officer for the Genentech Foundation, while ... Global Head of Business Development and Licensing for Roche ...
(Date:9/18/2014)... 18, 2014 Relmada Therapeutics, Inc., (OTCQB: RLMD), ... of chronic pain, announced today that it has appointed ... of  Senior Director of Clinical Development. During ... established and led successful global clinical operations teams, in ... facilitate the clinical development of numerous therapeutics and diagnostics ...
(Date:9/18/2014)... new expert panel report, Improving Medicines for Children ... by the Council of Canadian Academies, addresses the importance ... year about half of Canada,s ... Much of this prescribing is done off-label (i.e. the ... risks. Children have historically been excluded in ...
Breaking Medicine Technology:Nexvet Appoints Ashraf Hanna and Joseph McCracken to Board of Directors 2Nexvet Appoints Ashraf Hanna and Joseph McCracken to Board of Directors 3Relmada Therapeutics, Inc. Appoints Christopher W. James As Senior Director of Clinical Development 2Studying medicines in children is always possible and is in their best interest, finds Expert Panel 2Studying medicines in children is always possible and is in their best interest, finds Expert Panel 3
(Date:9/18/2014)... One of the most capable and ... ShandsCair Flight Program’s new EC155 B1, will ... at the Air Medical Transport Conference (AMTC), Sept. 22-24, ... into service ShandsCair EC155 and the Vanderbilt University ... AMTC highlight Airbus Helicopters broad, industry leading line-up of ...
(Date:9/18/2014)... THURSDAY, Sept. 18, 2014 (HealthDay News) -- Daily supplements ... protect against the development of age-related cataracts among men, ... suggested that one or both could help prevent cataracts. ... Women,s Hospital and Harvard Medical School in Boston, and ... of selenium and vitamin E. The trial was initially ...
(Date:9/18/2014)... UT (PRWEB) September 18, 2014 Thousands ... will be recognizing their shared fundraising impact on 127 ... Sept. 25. , The first-ever Dance Marathon Day will ... $20 million projected to be raised by college and ... CMN Hospital. Donations generated through Dance Marathon campus programs ...
(Date:9/18/2014)... A group of international scientists have developed a new ... here . , The Wildlife Conservation Society (WCS)-led ... Tropical Diseases , describes the use of fecal samples ... have been exposed to the virus. This represents a ... can potentially change the way Ebola virus is studied ...
(Date:9/18/2014)... the Ebola virus invoke scary scenarios of deadly epidemics, ... are still providing researchers with new insights on how ... published online Sept. 18, 2014, in the journal ... Medical School Singapore detail how the Yersinia pestis bacteria ... the lymph nodes and eventually ride into the lungs ...
Breaking Medicine News(10 mins):Health News:Airbus Helicopters Inc. Features Industry-leading Models at AMTC 2Health News:Airbus Helicopters Inc. Features Industry-leading Models at AMTC 3Health News:Airbus Helicopters Inc. Features Industry-leading Models at AMTC 4Health News:Vitamin E, Selenium Supplements Don't Seem to Prevent Cataracts 2Health News:250 Campuses Usher in School Year of Saving Kids’ Lives During First-Ever “Dance Marathon Day” on Sept. 25 2Health News:Research yields a game changer for improving understanding of Ebola and great apes 2Health News:Research yields a game changer for improving understanding of Ebola and great apes 3Health News:New insights on an ancient plague could improve treatments for infections 2
... , PASO ROBLES, Calif., July 28 ... California, will make silicone micro-implants such as surgical drains, catheter ... not routine is the incredibly precise tolerances demanded of these ... achieving consistently precise results to within .001 inch is no ...
... , MAITLAND, Fla. , July 28 ... treatment for infants with plagiocephaly and other head shape abnormalities, opened ... The Center currently also has offices in the Baltimore and Dallas ... orthoses, also commonly referred to as a cranial helmets or headbands. ...
... HARBIN, China, July 28 /PRNewswire-Asia-FirstCall/ -- China ... Company") (Nasdaq: CSKI ), a,leading fully integrated ... China ("PRC"), today announced that the,Company is scheduled to ... in early August, 2009. , ...
... , VANCOUVER, July 28 /PRNewswire-FirstCall/ - QLT Inc. (NASDAQ: ... "Company") today announced encouraging interim data from an ongoing ... the punctal plug delivery system. These studies are part ... QLT,s wholly-owned subsidiary, QLT Plug Delivery, Inc. , Preliminary ...
... , , THE WOODLANDS, Texas, ... LXRX ), a biopharmaceutical company focused on discovering and developing breakthrough ... financial results for the three months and six months ended June 30, ... progress, including the recent initiation of a Phase 2 study of LX1032 ...
... MINNEAPOLIS, July 28 ATS Medical, Inc. (Nasdaq: ATSI ... that it will participate in two upcoming investor conferences. ... The Company will participate in the 9th Annual BMO ... in New York. Michael Kramer, CFO of ATS Medical, will ...
Cached Medicine News:Health News:When You Make Things That Get Implanted in People, Small Things Count 2Health News:New STAR Cranial Center of Excellence Offers Cutting-Edge Treatment to Central Florida Infants 2Health News:New STAR Cranial Center of Excellence Offers Cutting-Edge Treatment to Central Florida Infants 3Health News:New STAR Cranial Center of Excellence Offers Cutting-Edge Treatment to Central Florida Infants 4Health News:New STAR Cranial Center of Excellence Offers Cutting-Edge Treatment to Central Florida Infants 5Health News:China Sky One Medical, Inc. to Conduct Non-Deal Roadshow in Hong Kong and Singapore 2Health News:QLT announces interim data from a Phase II clinical trial and a device study for the Punctal Plug Drug Delivery System 2Health News:QLT announces interim data from a Phase II clinical trial and a device study for the Punctal Plug Drug Delivery System 3Health News:QLT announces interim data from a Phase II clinical trial and a device study for the Punctal Plug Drug Delivery System 4Health News:QLT announces interim data from a Phase II clinical trial and a device study for the Punctal Plug Drug Delivery System 5Health News:QLT announces interim data from a Phase II clinical trial and a device study for the Punctal Plug Drug Delivery System 6Health News:QLT announces interim data from a Phase II clinical trial and a device study for the Punctal Plug Drug Delivery System 7Health News:Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 Second Quarter Financial Results 2Health News:Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 Second Quarter Financial Results 3Health News:Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 Second Quarter Financial Results 4Health News:Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 Second Quarter Financial Results 5Health News:Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 Second Quarter Financial Results 6Health News:Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 Second Quarter Financial Results 7Health News:Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 Second Quarter Financial Results 8Health News:ATS Medical to Participate at Upcoming Investor Conferences 2
... Constructed of optical steel base ... overlay. Comes with custom fitted ... create a seal to the ... from oblique angle exposure. Includes ...
... protection Properly manufactured radiation protective eyewear ... Our high quality frames and materials offer ... weight. Our lenses are made of Schott ... industry standards. Most Pulse Glasses are offered ...
... designed with the safety and comfort of the ... (also called SF-6) leaded glass, the industry standard ... as set for optical clarity, visible light transmission, ... is protecting your eyes, it also helps you ...
B-52 Wrap Frame...
Medicine Products: